Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Oncotype DX® Colon Recurrence Score

The Oncotype DX Colon Recurrence Score analyzes the expression of 12 genes to predict the risk of recurrence in patients with Stage II and Stage III colon cancer.

Evidence-based context for fast calculator use

Purpose:
Oncotype DX Colon Recurrence Score estimates recurrence risk in stage II/III colon cancer to guide adjuvant chemotherapy decision-making.
Population:
patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model
Factors:
Recurrence Score, Tumor Stage, MMR Status
Reference:
Gray R, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029 (QUASAR). (See also: Yothers G, et al. J Clin Oncol. 2013;31:6812-6819).
HomeOncotype DX® Colon Recurrence Score
Pin your most used calculators here by clicking the star in the dropdown.

Oncotype DX® Colon Recurrence Score

Clinical Context & Background

The Oncotype DX Colon Recurrence Score analyzes the expression of 12 genes to predict the risk of recurrence in patients with Stage II and Stage III colon cancer. It helps guide the decision for adjuvant chemotherapy, particularly in Stage II disease (T3N0, MMR-P).
Primary Source EvidenceGray R, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029 (QUASAR). (See also: Yothers G, et al. J Clin Oncol. 2013;31:6812-6819).
Formula Logic
Score 0-100 based on gene expression.

Reference Data

Recurrence ScoreRisk GroupRecurrence Risk (3y)
0 - 29Low Risk12% (approx)
30 - 40Intermediate Risk18% (approx)
41 - 100High Risk22% - 30%+

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Oncotype DX® Colon Recurrence Score when oncotype DX Colon Recurrence Score estimates recurrence risk in stage II/III colon cancer to guide adjuvant chemotherapy decision-making.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 29 through 41 - 100.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary site, histology, stage, surgery status, systemic-treatment timing, and disease-specific guideline before applying the result.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer thresholds across colorectal, GIST, gastric, appendiceal, and other peritoneal malignancies.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model

How to apply this result

For a representative case, verify Recurrence Score, Tumor Stage, MMR Status, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

GI, GIST & Peritoneal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Modified Glasgow Prognostic Score (mGPS)Fong Clinical Risk Score (CRS)Peritoneal Carcinomatosis Index (PCI)

Frequently Asked Questions

When should Oncotype DX® Colon Recurrence Score be used?

Use it for patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model when all required inputs and the intended clinical setting are confirmed.

Can Oncotype DX® Colon Recurrence Score determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.